Literature DB >> 12356793

Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.

F J Boswell1, J M Andrews, G Jevons, R Wise.   

Abstract

In this study the in vitro activities and pharmacodynamic properties of moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin were compared on recently isolated respiratory pathogens and strains of Streptococcus pneumoniae with known mechanisms of fluoroquinolone resistance. In addition, the resistance selection frequencies of moxifloxacin and levofloxacin on three recently isolated respiratory pathogens and four strains of S. pneumoniae with known mechanisms of fluoroquinolone resistance were investigated. The four fluoroquinolones had similar activities against both Moraxella catarrhalis (MIC(90)s 0.015-0.06 mg/L) and Haemophilus influenzae (MIC(90)s 0.008-0.03 mg/L). More marked differences in activity were noted with S. pneumoniae, with MIC(90)s of 0.25, 1, 0.5 and 0.03 mg/L for moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin, respectively. With the S. pneumoniae strains, the four fluoroquinolones exhibited similar concentration-dependent time-kill kinetics. The resistance selection frequencies of levofloxacin were higher than those of moxifloxacin at concentrations equivalent to those at the end of the dosing interval. Therefore moxifloxacin may have less of an impact on the development of resistance than levofloxacin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356793     DOI: 10.1093/jac/dkf152

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Gatifloxacin Therapy in Otitis Media in Children.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

3.  Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; P Moine; C Cherbuliez; G Peytavin; B Fantin; T Köhler
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.

Authors:  H Portier; C Brambilla; M Garre; F Paganin; P Poubeau; P Zuck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

5.  In vitro activities of levofloxacin and comparable agents against middle ear fluid, nasopharyngeal, and oropharyngeal pathogens obtained from Costa Rican children with recurrent otitis media or failing other antibiotic therapy.

Authors:  Carolina Soley; Adriano Arguedas; Wendy Porras; Silvia Guevara; Cecilia Loaiza; Alexandra Pérez; Guillermo Rincón; Malka Schultz; Jorge Arguedas; Roberto Brilla
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 6.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Effect of calcium carbonate on bioavailability of orally administered gemifloxacin.

Authors:  M W Pletz; P Petzold; A Allen; O Burkhardt; H Lode
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.

Authors:  Peter Ball
Journal:  Curr Ther Res Clin Exp       Date:  2003-11

Review 9.  Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.

Authors:  Jack B Anon
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.